Valuation: Prothena Corporation plc

Market Cap 485M 416M 389M 356M 668M 46.42B 677M 4.59B 1.79B 23.32B 1.82B 1.78B 77.12B P/E 2026 *
85.9x
P/E 2027 * -10.2x
Enterprise Value 485M 416M 389M 356M 668M 46.42B 677M 4.59B 1.79B 23.32B 1.82B 1.78B 77.12B EV / Sales 2026 *
5.83x
EV / Sales 2027 * 19.9x
Free-Float
77.89%
Yield 2026 *
-
Yield 2027 * -
1 day+4.65%
1 week+6.66%
Current month+16.38%
1 month+8.00%
3 months+0.43%
6 months+4.77%
Current year-1.05%
1 week 8.58
Extreme 8.58
9.52
1 month 8
Extreme 8
9.52
Current year 7.73
Extreme 7.73
11.8
1 year 7.73
Extreme 7.73
11.8
3 years 4.32
Extreme 4.32
57.78
5 years 4.32
Extreme 4.32
79.75
10 years 4.32
Extreme 4.32
79.75
Manager TitleAgeSince
Chief Executive Officer 57 30/09/2016
Director of Finance/CFO 52 01/04/2013
Chief Operating Officer 52 29/09/2021
Director TitleAgeSince
Chairman 76 20/12/2012
Director/Board Member 72 20/12/2012
Director/Board Member 63 20/12/2012
Date Insider Type Main position Quantity % Market Cap.
20/08/26 Buy 50,000 0.0955%
18/08/26 Don -627,553 1.1987%
10/08/26 Don 251,553 0.4805%
Change 5-day change 1-year change 3-year change Capi.($)
+4.65%+6.66%+10.40%-83.47% 485M
-3.00%+2.27%+77.60%+109.33% 72.12B
+1.90%+23.53%+56.60%+97.76% 65.85B
+5.12%+25.22%+5.24%-0.82% 29.28B
+0.55%+1.64%-5.15%+471.68% 27.47B
+2.74%+12.98%+62.84%+28.14% 26.7B
+0.47%+6.12%+36.66%-13.79% 20.06B
+1.82%-6.67%+247.46%+393.10% 18.22B
+0.94%+3.36%+18.55%+532.94% 16.4B
+0.73%+5.54%+39.71%+153.07% 13.4B
Average +1.59%+8.19%+54.99%+168.80% 29B
Weighted average by Cap. +0.75%+9.48%+58.96%+157.40%

Financials

2026 *2027 *
Net sales 83.16M 71.23M 66.65M 61.01M 114M 7.96B 116M 787M 307M 4B 312M 305M 13.22B 24.38M 20.88M 19.54M 17.88M 33.56M 2.33B 34.01M 231M 90.01M 1.17B 91.53M 89.53M 3.88B
Net income 6.22M 5.33M 4.99M 4.57M 8.57M 596M 8.68M 58.94M 22.98M 299M 23.37M 22.86M 989M -49.57M -42.47M -39.73M -36.37M -68.26M -4.74B -69.16M -469M -183M -2.38B -186M -182M -7.88B
Net Debt - -
Logo Prothena Corporation plc
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.
Employees
67
Date Price Change Volume
21/08/26 $9.450 +4.65% 376,043
20/08/26 $9.030 -2.80% 345,968
19/08/26 $9.290 +6.66% 385,539
18/08/26 $8.710 -1.91% 248,560
17/08/26 $8.880 +0.23% 365,922
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
9.450USD
Average target price
21.40USD
Spread / Average Target
+126.46%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PRTA Stock